Here are five highlights:
1. Takeda aims to pave the way for translating science into treatment paradigms and patient-centered support, with initiatives directed at digital innovation and IBD and immunology and IBD.
2. During the three-year partnership, the University of Chicago will work to establish a unique patient-physician digital platform that communicates real-time disease status, collates environmental, molecular, genetic and microbiome factors for each patient and creates a system for identifying personalized IBD therapy.
3. Mount Sinai will focus on immunology in IBD, including the discovery of novel paradigms of lymphocytic homing to the colon, identifying the effect of the microbiome on homing to the colon and exploring therapeutic cell-based approaches to suppress intestinal inflammation.
4. The collaboration was facilitated through Mount Sinai Innovation Partners, an internal business unit of the Mount Sinai Health System.
5. Takeda Pharmaceutical is a global pharmaceutical company focused on oncology, gastroenterology and central nervous system therapeutic areas.
More articles on GI & endoscopy:
FTC requests more information from Pfizer & Allergan on pending merger: 5 takeaways
FDA clears Medtronic’s PillCam COLON 2 capsule for expanded indication: 4 things to know
Brighter Health Network, Medspira partner for distribution of anorectal manometry system: 3 points
